Skip to main content
KALA logo

KALA · KALA BIO, Inc. · Documents

Track KALA — free
$2.71 -0.31 (-10.28%) At close · Nov 20 Q2 2022 earnings call transcript
Market Cap
$1.74M
Shares
644,660
Volume · Nov 20 19.23K Avg daily vol (5 sessions) 17.3K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $0 10-K filed Apr 15, 2026 Quarterly report FY2026 Q2 Net loss $1.58M 10-Q filed Aug 19, 2026 Latest results Quarterly net loss falls approximately 90% year over year 8-K filed Nov 9, 2026 Earnings call Q2 2022 earnings call Held Aug 11, 2022
2026
Nov 16
Current report 8-K Events of Nov 13
Nasdaq conditionally retains listing through February 23, 2027

Nasdaq granted KALA BIO, Inc. continued listing on The Nasdaq Capital Market, requiring a closing bid price of at least $1.00 per share from November 30, 2026 through February 23, 2027. The company had received a bid-price deficiency notice for July 16, 2026 through August 26, 2026.

Other events
2 source passages
On November 13, 2026, the Panel granted the Company’s request to continue its listing on Nasdaq subject to the following conditions: (i) the Company shall evidence a closing bid price of at least $1.00 per share for ten consecutive business days by November 30, 2026; (ii) the Company must maintain a closing bid price of at least $1.00 for each trading day after November 30, 2026 until February 23, 2027; and (iii) if the Company becomes non-compliant with any other Nasdaq listing rule prior to February 23, 2027, the Company will be allowed seven days to advise the Panel on the Company’s plan to cure the listing deficiency and the Panel shall determine whether to grant the Company an exception to cure the deficiency or delist the Company. On August 27, 2026, KALA BIO, Inc. (the “Company”) received a letter (the “Staff Determination Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff has determined that the closing bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), has been below $1.00 per share for the previous 30 consecutive business days (from July 16, 2026 through August 26, 2026) and, as a result, the Company is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2). Open the document at this passage
Nov 13
Late filing notice NT 10-Q
Quarterly filing delayed for liquidity analysis

KALA BIO, Inc. needs additional time to complete its analysis and disclosure regarding liquidity and capital resources for the quarter ended September 30, 2026, and expects to file no later than the fifth calendar day following the prescribed filing deadline.

2 source passages
KALA BIO, Inc. (the “Company”) will not, without unreasonable effort and expense, be able to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (the “Form 10-Q”) within the prescribed time period because the Company requires additional time to complete its analysis and disclosure regarding its liquidity and capital resources. The Company anticipates that it will file the Form 10-Q no later than the fifth calendar day following the prescribed filing date. Open the document at this passage
Nov 12
Current report 8-K
1-for-30 reverse stock split effective November 13, 2026

KALA BIO will effect a 1-for-30 reverse stock split, reducing outstanding common shares from 19,339,786 to approximately 644,659; split-adjusted Nasdaq trading begins November 16, 2026 under KALA.

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Other events
4 source passages
KALA BIO, Inc. (NASDAQ: KALA) (“KALA BIO” or the “Company”), today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the “common stock”) at a ratio of 1 post-split share for every 30 pre-split shares. The reverse stock split will become effective at 4:05 p.m. on Friday, November 13, 2026. The reverse stock split will reduce the number of shares of the Company’s common stock outstanding from 19,339,786 shares to approximately 644,659 shares. The Company’s common stock will continue to be traded on the Nasdaq Capital Market under the symbol KALA and will begin trading on a split-adjusted basis when the market opens on Monday, November 16, 2026. Open the document at this passage
Nov 9
Current report 8-K
Quarterly net loss falls approximately 90% year over year

KALA BIO, Inc. reported preliminary third-quarter 2026 net loss of approximately $0.8 million, down from $7.6 million, and approximately $7.0 million in cash, cash equivalents and short-term investments with no debt.

Financial results
4 source passages
KALA BIO, Inc. (Nasdaq: KALA) today announced preliminary unaudited financial results for the quarter ended September 30, 2026. Net loss of approximately $0.8 million for the third quarter of 2026, compared to $7.6 million for the third quarter of 2025. Cash, cash equivalents and short-term investments of approximately $7.0 million as of September 30, 2026, with no debt. We reduced our quarterly net loss by approximately 90% year over year and continue to develop the initiatives we have put in motion. Open the document at this passage
Nov 3
Current report 8-K
Reverse split approved within 1-for-2 and 1-for-300 bounds

KALA BIO, Inc. stockholders approved a reverse stock split at a ratio of not less than 1-for-2 and not greater than 1-for-300. The Board of Directors will determine the timing and publicly announce the selected ratio.

Shareholder vote results
2 source passages
KALA BIO, INC. The Company’s stockholders voted to approve an amendment to the Restated Certificate of Incorporation to effect a reverse stock split of the Common Stock at a ratio of not less than 1-for-2 and not greater than 1-for-300 at such time as the Company’s Board of Directors shall determine, in its sole discretion, and to be included in a public announcement. Open the document at this passage
Sep 24
Proxy statement DEF 14A Meeting Nov 3, 2026
Proxy statement

KALA BIO, INC. will hold its 2026 annual meeting on November 3, 2026, seeking stockholder approval for a common-stock reverse split at a ratio of not less than 1-for-2 and not greater than 1-for-300, director elections and other proposals.

Read from the first part of this long document
Jul 23
Current report 8-K Events of Jul 22
Other events AI summary on its way
Apr 15
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $0 Net loss $26.98M Diluted EPS -$3.31
Jan 2
Current report 8-K Events of Dec 26
Other events AI summary on its way
2025
Showing 1–50 of 176 documents
Key facts CIK 1479419 CUSIP 483119301 13F (30d) 23 filings 19 filers Visit website Investor relations